Literature DB >> 20438402

Rare histological patterns of prostatic ductal adenocarcinoma.

Thomas K Lee1, Jeremy S Miller, Jonathan I Epstein.   

Abstract

AIMS: Prostatic ductal adenocarcinomas account for 1% of prostate cancers. Most commonly, these lesions grow in large cribriform and/or papillary patterns or, as recently described, in a manner resembling prostatic intraepithelial neoplasia (i.e., 'PIN-like' prostatic ductal adenocarcinoma). This study aims to report rare variants of ductal adenocarcinoma.
METHODS: Ten cases of rare patterns of prostatic ductal adenocarcinoma that have not been formally investigated prior to this study, primarily from one author's consultation service (1987-2009), were selected.
RESULTS: Two (n = 2) cases were prostatic ductal adenocarcinoma with mucinous and goblet cell features. Three (n = 3) cases are the first described cases of foamy gland prostatic ductal adenocarcinoma. Other unique cases were prostatic duct adenocarcinomas with associated Paneth cell-like neuroendocrine (n = 2), micropapillary (n = 2), and cystic papillary features (n = 1). Prostatic origin was confirmed with immunohistochemical studies for prostate specific antigen (PSA), P501S, and prostate specific membrane antigen (PSMA). High-grade PIN was ruled out with negative stains for high molecular weight cytokeratin (HMWCK) and p63. Four prostatic ductal adenocarcinomas had no evidence of disease at 2-8 years follow-up: foamy gland, Paneth cell-like, and micropapillary (two cases). One mucinous prostatic ductal adenocarcinoma resulted in the patient's death and the other mucinous case was alive at 7 years and 2 months, yet with no information as to status of disease. The remaining four cases were lost to follow-up, died of other causes, or were recent.
CONCLUSIONS: In summary, we report several rare and unique histological patterns of prostatic ductal adenocarcinoma. The practical importance of recognising these histological variations is that in some cases they may be misdiagnosed as non-prostatic tumours. These unusual cases also provide further support for the relationship between acinar and ductal adenocarcinoma.

Entities:  

Mesh:

Year:  2010        PMID: 20438402     DOI: 10.3109/00313021003767314

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  9 in total

Review 1.  The update of prostatic ductal adenocarcinoma.

Authors:  Tantan Liu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

2.  Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.

Authors:  Kenneth A Iczkowski; Kathleen C Torkko; Gregory R Kotnis; R Storey Wilson; Wei Huang; Thomas M Wheeler; Andrea M Abeyta; Francisco G La Rosa; Shelly Cook; Priya N Werahera; M Scott Lucia
Journal:  Am J Clin Pathol       Date:  2011-07       Impact factor: 2.493

Review 3.  DNA methylation as a dynamic regulator of development and disease processes: spotlight on the prostate.

Authors:  Kimberly P Keil; Chad M Vezina
Journal:  Epigenomics       Date:  2015       Impact factor: 4.778

4.  Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate.

Authors:  Francesco Chierigo; Marco Borghesi; Christoph Würnschimmel; Rocco Simone Flammia; Benedikt Horlemann; Gabriele Sorce; Benedikt Höh; Zhe Tian; Fred Saad; Markus Graefen; Michele Gallucci; Alberto Briganti; Francesco Montorsi; Felix K H Chun; Shahrokh F Shariat; Guglielmo Mantica; Nazareno Suardi; Carlo Terrone; Pierre I Karakiewicz
Journal:  Int Urol Nephrol       Date:  2021-11-19       Impact factor: 2.370

Review 5.  Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.

Authors:  Nithesh Ranasinha; Altan Omer; Yiannis Philippou; Eli Harriss; Lucy Davies; Ken Chow; Paolo M Chetta; Andrew Erickson; Timothy Rajakumar; Ian G Mills; Richard J Bryant; Freddie C Hamdy; Declan G Murphy; Massimo Loda; Christopher M Hovens; Niall M Corcoran; Clare Verrill; Alastair D Lamb
Journal:  BJUI Compass       Date:  2021-01-05

6.  Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens.

Authors:  Amanda H Seipel; Fredrik Wiklund; N Peter Wiklund; Lars Egevad
Journal:  Virchows Arch       Date:  2013-02-27       Impact factor: 4.064

7.  Prostate carcinomas mimicking a digestive malignancy.

Authors:  Sorin Dema; Alis Liliana Carmen Dema; Sorina Tăban; Bianca Roxana Natarâş; Livius Cosmin Daminescu; Ciprian Constantin Duţă; Alin Adrian Cumpănaş; Tiberiu Răzvan Bardan
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

8.  Clinicopathological features of prostate ductal carcinoma: matching analysis and comparison with prostate acinar carcinoma.

Authors:  Aram Kim; Taekmin Kwon; Dalsan You; In Gab Jeong; Heounjeong Go; Yong Mee Cho; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  J Korean Med Sci       Date:  2015-03-19       Impact factor: 2.153

9.  Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1+ prostate luminal cells.

Authors:  Oh-Joon Kwon; Li Zhang; Deyong Jia; Li Xin
Journal:  Oncogene       Date:  2020-10-27       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.